Pluristem Therapeutics, Inc. (PSTI) PT Set at $2.00 by Maxim Group

Pluristem Therapeutics, Inc. (NASDAQ:PSTI) has been assigned a $2.00 target price by equities researchers at Maxim Group in a report issued on Thursday. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Maxim Group’s target price points to a potential upside of 14.94% from the company’s previous close.

PSTI has been the subject of a number of other reports. Seaport Global Securities reissued a “buy” rating and issued a $5.00 price target on shares of Pluristem Therapeutics in a research report on Friday, October 6th. HC Wainwright set a $4.00 price target on shares of Pluristem Therapeutics and gave the stock a “buy” rating in a research report on Thursday, August 17th. ValuEngine raised shares of Pluristem Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Monday, October 2nd. Finally, Zacks Investment Research lowered shares of Pluristem Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, September 22nd. Two analysts have rated the stock with a sell rating and four have issued a buy rating to the company’s stock. Pluristem Therapeutics currently has a consensus rating of “Hold” and an average price target of $4.13.

Pluristem Therapeutics (NASDAQ:PSTI) traded up 2.2586% during midday trading on Thursday, hitting $1.7793. 852,451 shares of the stock traded hands. The company’s 50 day moving average is $1.47 and its 200-day moving average is $1.35. Pluristem Therapeutics has a one year low of $1.04 and a one year high of $2.02. The company’s market cap is $173.43 million.

WARNING: “Pluristem Therapeutics, Inc. (PSTI) PT Set at $2.00 by Maxim Group” was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this article on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this article can be viewed at https://ledgergazette.com/2017/10/19/pluristem-therapeutics-inc-psti-pt-set-at-2-00-by-maxim-group.html.

An institutional investor recently raised its position

PSTI has been the subject of a number of other reports. Seaport Global Securities reissued a “buy” rating and issued a $5.00 price target on shares of Pluristem Therapeutics in a research report on Friday, October 6th. HC Wainwright set a $4.00 price target on shares of Pluristem Therapeutics and gave the stock a “buy” rating in a research report on Thursday, August 17th. ValuEngine raised shares of Pluristem Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Monday, October 2nd. Finally, Zacks Investment Research lowered shares of Pluristem Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, September 22nd. Two analysts have rated the stock with a sell rating and four have issued a buy rating to the company’s stock. Pluristem Therapeutics currently has a consensus rating of “Hold” and an average price target of $4.13.

Pluristem Therapeutics (NASDAQ:PSTI) traded up 2.2586% during midday trading on Thursday, hitting $1.7793. 852,451 shares of the stock traded hands. The company’s 50 day moving average is $1.47 and its 200-day moving average is $1.35. Pluristem Therapeutics has a one year low of $1.04 and a one year high of $2.02. The company’s market cap is $173.43 million.

WARNING: “Pluristem Therapeutics, Inc. (PSTI) PT Set at $2.00 by Maxim Group” was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this article on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this article can be viewed at https://ledgergazette.com/2017/10/19/pluristem-therapeutics-inc-psti-pt-set-at-2-00-by-maxim-group.html.

An institutional investor recently raised its position in Pluristem Therapeutics stock. Jane Street Group LLC boosted its holdings in shares of Pluristem Therapeutics, Inc. (NASDAQ:PSTI) by 62.4% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 108,830 shares of the biotechnology company’s stock after acquiring an additional 41,796 shares during the quarter. Jane Street Group LLC owned approximately 0.11% of Pluristem Therapeutics worth $134,000 at the end of the most recent reporting period. 4.47% of the stock is currently owned by institutional investors and hedge funds.

Pluristem Therapeutics Company Profile

Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.

Receive News & Ratings for Pluristem Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply